Статус: | Completed |
Фаза: | Phase 1 |
Начало: | 29 октября 2015 г. |
Окончание: | 10 мая 2016 г. |
Описание: | The purpose of the current phase I study was to establish bioequivalence, safety, and tolerance of single 300 IU subcutaneous dose of follitropin alfa biosimilar (Primapur) in comparison to that of reference follitropin alfa preparation (Gonal-F) in healthy young female volunteers. |
смотреть на ClinicalTrials.gov |